Thymosin Alpha-1 vs Vilon
A side-by-side research comparison of Thymosin Alpha-1 and Vilon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Thymosin Alpha-1 | Vilon |
|---|---|---|
| Full name | Thymosin Alpha-1 (Thymalfasin) | Vilon (Lys-Glu Dipeptide Immune Bioregulator) |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Research compound (peptide bioregulator) |
| Mechanism | Activates toll-like receptors (TLR2, TLR9) on dendritic cells, promotes T-cell maturation and differentiation, enhances NK cell cytotoxicity, and modulates cytokine profiles. | As a very short signal peptide (Lys-Glu), it is proposed to bind DNA and modulate gene expression in immune and other tissues, influencing chromatin activity, cytokine balance, and cellular aging markers. |
| Molecular weight | 3108.3 Da | ~275 Da |
| Half-life | ~2-3 hours | Short (peptide) |
| Bioavailability | ~85% subcutaneous | Oral (encapsulated) or subcutaneous |
| Typical dose | 1.6-3.2 mg | ~1-2 capsules/day or short injectable courses |
| Frequency | 2-3x per week | Once daily |
| Route | Subcutaneous injection | Oral capsule or subcutaneous |
Thymosin Alpha-1 reported benefits
- Enhanced T-cell immunity
- Anti-viral activity
- Dendritic cell activation
- Cancer immunosurveillance
- Vaccine adjuvant effects
Vilon reported benefits
- Immune regulation support
- Gene-expression modulation (proposed)
- Anti-aging tissue effects (proposed)
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.